Reports

Industry Research Reports

Home > Reports > Medical Care > Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Medical Care

Published Date: 2026-01-04

Pages: 100 Pages

Report ld: 5558885

application for samples

Request Sample

Custom reports

Customized Report

  • Description selected
  • Table of Contents selected
  • Table of Figures selected
  • Related Reports selected
  • PDFPDF Downloadselected
  • Description selected
  • Table of Contents selected
  • Table of Figures selected
  • Related Reports selected
  • PDFPDF Downloadselected

RNAi for Therapeutic Market Size(US$)

den_QYR1
cagr

CAGR 2026-2032

27.5%

marketSize

Market Size,2032

USD 16,370

Million

Market Snapshot

Market Size in 2026 (Value)
US$ 3,814 million
Market Forecast in 2032(Value)
US$ 16,370 million
CAGR
27.5%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global RNAi for Therapeutic market size was US$ 3058 million in 2025 and is forecast to reach a readjusted size of US$ 16370 million by 2032 with a CAGR of 27.5% during the forecast period 2026-2032.

RNA interference (RNAi) therapeutics is an advanced molecular medicine technology that utilizes double-stranded RNA molecules (such as siRNA or shRNA) to selectively silence target gene expression, thereby blocking pathogenic gene transcription or translation to achieve precise treatment of various genetic disorders, rare diseases, cancers, and viral infections. Without altering the DNA sequence, RNAi therapy offers reversible, highly specific, and low-toxicity interventions at the RNA level. Since the approval of the first RNAi drug, the field has rapidly transitioned from research to commercialization, showing immense potential in targeting the liver, nervous system, and oncology. With breakthroughs in delivery systems and expanding clinical pipelines, RNAi therapeutics is emerging as a strategic pillar in precision medicine and gene therapy industries.

The global deployment of RNAi therapeutics is accelerating, driven by multiple dimensions: breakthroughs in genomics and RNA biology have enabled higher-precision drug design; advancements in novel delivery technologies such as lipid nanoparticles (LNP) and GalNAc conjugates have significantly improved targeting efficiency to the liver and other tissues; and fast-track review policies by regulatory agencies in multiple countries have shortened the path from R&D to commercialization. Leading pharmaceutical and biotech companies are actively expanding the range of clinical indications through mergers, acquisitions, and collaborations, facilitating the market rollout of RNAi therapies in rare diseases, metabolic disorders, and cardiovascular diseases.Despite its disruptive potential, RNAi therapeutics faces technical, commercial, and regulatory hurdles. Delivery efficiency and tissue specificity remain key bottlenecks, especially in achieving effective delivery to the central nervous system and solid tumors. Additionally, RNAi molecules may trigger non-specific immune responses or off-target effects, affecting both safety and efficacy. From a business perspective, high production costs and stringent quality control standards constrain scalability and profit margins. Intellectual property barriers and the concentration of core patents among a few leading companies further raise the technical and legal thresholds for new entrants.Demand in downstream markets is becoming increasingly segmented and diversified. Rare disease treatment, lacking effective therapies, is highly reliant on RNAi solutions, making it an early commercialization breakthrough. Cardiovascular and metabolic diseases, with their vast patient populations, offer long-term growth potential. In oncology and immunotherapy, RNAi is forming novel combination approaches with checkpoint inhibitors, CAR-T, and other treatments. With the rise of personalized medicine and companion diagnostics, RNAi therapies will become more deeply integrated into precision stratification and targeted intervention clinical pathways, driving demand toward higher efficiency, safety, and controllability.

The global RNAi for Therapeutic market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.

MARKET SEGMENTATION

By Company

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Arrowhead
  • Silence Therapeutics
  • Benitec Biopharma
  • Phio Pharmaceuticals
  • RXi Pharmaceuticals
  • Arrakis Therapeutics
  • Benitec Biopharma
  • miRagen Therapeutics
  • Sylentis
  • Gradalis
  • Sirnaomics
  • Silenseed

Consumption by Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Segment by Type

  • siRNA
  • miRNA
  • shRNA

Segment by Application

  • Cancer
  • Cardiovascular
  • HBV
  • Others

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the RNAi for Therapeutic value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region
Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

den_ic6
Product mix optimization based on local practices
Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

den_ic6
Competitor tactics in fragmented vs. consolidated markets
Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

den_ic6
Full Research Coverage
Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

den_ic6
19 Years Industry Expertise
19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

den_ic6
24/7 Fast Report Delivery
24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

den_ic6
Localized Strategic Analysis
Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

den_ic6
Market entry risks/opportunities by region
Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

den_ic6
Market entry risks/opportunities by region
Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

den_ic6
den_biaoTiZhungShi

TABLE OF CONTENTS

muLu

1 Report Overview

1.1 Study Scope

1.2 Market by Type

1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032

1.2.2 siRNA

1.2.3 miRNA

1.2.4 shRNA

1.3 Market by Application

1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032

1.3.2 Cancer

1.3.3 Cardiovascular

1.3.4 HBV

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

muLu

2 Global Growth Trends

2.1 Global RNAi for Therapeutic Market Perspective (2021-2032)

2.2 Global Market Size by Region: 2021 vs 2025 vs 2032

2.3 Global RNAi for Therapeutic Market Share by Revenue, by Region (2021-2026)

2.4 Global RNAi for Therapeutic Revenue Forecast by Region (2027-2032)

2.5 Major Regions and Emerging Markets Analysis

2.5.1 North America RNAi for Therapeutic Market Size and Prospective (2021-2032)

2.5.2 Europe RNAi for Therapeutic Market Size and Prospective (2021-2032)

2.5.3 China RNAi for Therapeutic Market Size and Prospective (2021-2032)

2.5.4 Japan RNAi for Therapeutic Market Size and Prospective (2021-2032)

2.5.5 Australia RNAi for Therapeutic Market Size and Prospective (2021-2032)

muLu

3 Breakdown Data by Type

3.1 Global RNAi for Therapeutic Historical Market Size by Type (2021-2026)

3.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2027-2032)

3.3 Representative Players for Different Types of RNAi for Therapeutic

muLu

4 Breakdown Data by Application

4.1 Global RNAi for Therapeutic Historical Market Size by Application (2021-2026)

4.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2027-2032)

4.3 New Sources of Growth in RNAi for Therapeutic Applications

muLu

5 Competitive Landscape by Players

5.1 Global Top Players by Revenue

5.1.1 Global Top RNAi for Therapeutic Players by Revenue (2021-2026)

5.1.2 Global RNAi for Therapeutic Market Share by Revenue, by Players (2021-2026)

5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

5.3 Players Covered: Ranking by RNAi for Therapeutic Revenue

5.4 Global RNAi for Therapeutic Market Concentration Analysis

5.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)

5.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2025

5.5 Global Key Players of RNAi for Therapeutic Head Offices and Areas Served

5.6 Global Key Players of RNAi for Therapeutic, Product and Application

5.7 Global Key Players of RNAi for Therapeutic, Date of Entry into This Industry

5.8 Mergers & Acquisitions, Expansion Plans

muLu

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America RNAi for Therapeutic Revenue by Company (2021-2026)

6.1.2 North America Market Size by Type

6.1.2.1 North America RNAi for Therapeutic Market Size by Type (2021-2026)

6.1.2.2 North America RNAi for Therapeutic Market Share by Type (2021-2026)

6.1.3 North America Market Size by Application

6.1.3.1 North America RNAi for Therapeutic Market Size by Application (2021-2026)

6.1.3.2 North America RNAi for Therapeutic Market Share by Application (2021-2026)

6.1.4 North America RNAi for Therapeutic Major Customers

6.1.5 North America Market Trends and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe RNAi for Therapeutic Revenue by Company (2021-2026)

6.2.2 Europe Market Size by Type

6.2.2.1 Europe RNAi for Therapeutic Market Size by Type (2021-2026)

6.2.2.2 Europe RNAi for Therapeutic Market Share by Type (2021-2026)

6.2.3 Europe Market Size by Application

6.2.3.1 Europe RNAi for Therapeutic Market Size by Application (2021-2026)

6.2.3.2 Europe RNAi for Therapeutic Market Share by Application (2021-2026)

6.2.4 Europe RNAi for Therapeutic Major Customers

6.2.5 Europe Market Trends and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China RNAi for Therapeutic Revenue by Company (2021-2026)

6.3.2 China Market Size by Type

6.3.2.1 China RNAi for Therapeutic Market Size by Type (2021-2026)

6.3.2.2 China RNAi for Therapeutic Market Share by Type (2021-2026)

6.3.3 China Market Size by Application

6.3.3.1 China RNAi for Therapeutic Market Size by Application (2021-2026)

6.3.3.2 China RNAi for Therapeutic Market Share by Application (2021-2026)

6.3.4 China RNAi for Therapeutic Major Customers

6.3.5 China Market Trends and Opportunities

6.4 Japan Market: Players, Segments, Downstream and Major Customers

6.4.1 Japan RNAi for Therapeutic Revenue by Company (2021-2026)

6.4.2 Japan Market Size by Type

6.4.2.1 Japan RNAi for Therapeutic Market Size by Type (2021-2026)

6.4.2.2 Japan RNAi for Therapeutic Market Share by Type (2021-2026)

6.4.3 Japan Market Size by Application

6.4.3.1 Japan RNAi for Therapeutic Market Size by Application (2021-2026)

6.4.3.2 Japan RNAi for Therapeutic Market Share by Application (2021-2026)

6.4.4 Japan RNAi for Therapeutic Major Customers

6.4.5 Japan Market Trends and Opportunities

6.5 Australia Market: Players, Segments, Downstream and Major Customers

6.5.1 Australia RNAi for Therapeutic Revenue by Company (2021-2026)

6.5.2 Australia Market Size by Type

6.5.2.1 Australia RNAi for Therapeutic Market Size by Type (2021-2026)

6.5.2.2 Australia RNAi for Therapeutic Market Share by Type (2021-2026)

6.5.3 Australia Market Size by Application

6.5.3.1 Australia RNAi for Therapeutic Market Size by Application (2021-2026)

6.5.3.2 Australia RNAi for Therapeutic Market Share by Application (2021-2026)

6.5.4 Australia RNAi for Therapeutic Major Customers

6.5.5 Australia Market Trends and Opportunities

muLu

7 Key Player Profiles

7.1 Alnylam Pharmaceuticals

7.1.1 Alnylam Pharmaceuticals Company Details

7.1.2 Alnylam Pharmaceuticals Business Overview

7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction

7.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026)

7.1.5 Alnylam Pharmaceuticals Recent Development

7.2 Arrowhead Pharmaceuticals

7.2.1 Arrowhead Pharmaceuticals Company Details

7.2.2 Arrowhead Pharmaceuticals Business Overview

7.2.3 Arrowhead Pharmaceuticals RNAi for Therapeutic Introduction

7.2.4 Arrowhead Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026)

7.2.5 Arrowhead Pharmaceuticals Recent Development

7.3 Arrowhead

7.3.1 Arrowhead Company Details

7.3.2 Arrowhead Business Overview

7.3.3 Arrowhead RNAi for Therapeutic Introduction

7.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2021-2026)

7.3.5 Arrowhead Recent Development

7.4 Silence Therapeutics

7.4.1 Silence Therapeutics Company Details

7.4.2 Silence Therapeutics Business Overview

7.4.3 Silence Therapeutics RNAi for Therapeutic Introduction

7.4.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026)

7.4.5 Silence Therapeutics Recent Development

7.5 Benitec Biopharma

7.5.1 Benitec Biopharma Company Details

7.5.2 Benitec Biopharma Business Overview

7.5.3 Benitec Biopharma RNAi for Therapeutic Introduction

7.5.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2021-2026)

7.5.5 Benitec Biopharma Recent Development

7.6 Phio Pharmaceuticals

7.6.1 Phio Pharmaceuticals Company Details

7.6.2 Phio Pharmaceuticals Business Overview

7.6.3 Phio Pharmaceuticals RNAi for Therapeutic Introduction

7.6.4 Phio Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026)

7.6.5 Phio Pharmaceuticals Recent Development

7.7 RXi Pharmaceuticals

7.7.1 RXi Pharmaceuticals Company Details

7.7.2 RXi Pharmaceuticals Business Overview

7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction

7.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026)

7.7.5 RXi Pharmaceuticals Recent Development

7.8 Arrakis Therapeutics

7.8.1 Arrakis Therapeutics Company Details

7.8.2 Arrakis Therapeutics Business Overview

7.8.3 Arrakis Therapeutics RNAi for Therapeutic Introduction

7.8.4 Arrakis Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026)

7.8.5 Arrakis Therapeutics Recent Development

7.9 Benitec Biopharma

7.9.1 Benitec Biopharma Company Details

7.9.2 Benitec Biopharma Business Overview

7.9.3 Benitec Biopharma RNAi for Therapeutic Introduction

7.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2021-2026)

7.9.5 Benitec Biopharma Recent Development

7.10 miRagen Therapeutics

7.10.1 miRagen Therapeutics Company Details

7.10.2 miRagen Therapeutics Business Overview

7.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction

7.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026)

7.10.5 miRagen Therapeutics Recent Development

7.11 Sylentis

7.11.1 Sylentis Company Details

7.11.2 Sylentis Business Overview

7.11.3 Sylentis RNAi for Therapeutic Introduction

7.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2021-2026)

7.11.5 Sylentis Recent Development

7.12 Gradalis

7.12.1 Gradalis Company Details

7.12.2 Gradalis Business Overview

7.12.3 Gradalis RNAi for Therapeutic Introduction

7.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2021-2026)

7.12.5 Gradalis Recent Development

7.13 Sirnaomics

7.13.1 Sirnaomics Company Details

7.13.2 Sirnaomics Business Overview

7.13.3 Sirnaomics RNAi for Therapeutic Introduction

7.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2021-2026)

7.13.5 Sirnaomics Recent Development

7.14 Silenseed

7.14.1 Silenseed Company Details

7.14.2 Silenseed Business Overview

7.14.3 Silenseed RNAi for Therapeutic Introduction

7.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2021-2026)

7.14.5 Silenseed Recent Development

muLu

8 RNAi for Therapeutic Market Dynamics

8.1 RNAi for Therapeutic Industry Trends

8.2 RNAi for Therapeutic Market Drivers

8.3 RNAi for Therapeutic Market Challenges

8.4 RNAi for Therapeutic Market Restraints

muLu

9 Research Findings and Conclusion

muLu

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

den_biaoTiZhungShi

TABLE OF FIGURES

muLu

List of Tables

Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market RNAi for Therapeutic Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global RNAi for Therapeutic Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global RNAi for Therapeutic Revenue Share by Region (2021-2026)
Table 6. Global RNAi for Therapeutic Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global RNAi for Therapeutic Revenue Share Forecast by Region (2027-2032)
Table 8. Global RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global RNAi for Therapeutic Market Share by Revenue, by Type (2021-2026)
Table 10. Global RNAi for Therapeutic Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global RNAi for Therapeutic Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global RNAi for Therapeutic Market Share by Revenue, by Application (2021-2026)
Table 15. Global RNAi for Therapeutic Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global RNAi for Therapeutic Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in RNAi for Therapeutic Applications
Table 18. Global RNAi for Therapeutic Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global RNAi for Therapeutic Market Share by Players (2021-2026)
Table 20. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2025)
Table 21. Ranking of Global Top RNAi for Therapeutic Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by RNAi for Therapeutic Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of RNAi for Therapeutic, Headquarters and Area Served
Table 24. Global Key Players of RNAi for Therapeutic, Product and Application
Table 25. Global Key Players of RNAi for Therapeutic, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America RNAi for Therapeutic Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America RNAi for Therapeutic Market Share by Revenue, by Company (2021-2026)
Table 29. North America RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe RNAi for Therapeutic Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe RNAi for Therapeutic Market Share by Revenue, by Company (2021-2026)
Table 33. Europe RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million)
Table 35. China RNAi for Therapeutic Revenue by Company (2021-2026) & (US$ Million)
Table 36. China RNAi for Therapeutic Market Share by Revenue, by Company (2021-2026)
Table 37. China RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million)
Table 38. China RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million)
Table 39. Japan RNAi for Therapeutic Revenue by Company (2021-2026) & (US$ Million)
Table 40. Japan RNAi for Therapeutic Market Share by Revenue, by Company (2021-2026)
Table 41. Japan RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million)
Table 42. Japan RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million)
Table 43. Australia RNAi for Therapeutic Revenue by Company (2021-2026) & (US$ Million)
Table 44. Australia RNAi for Therapeutic Market Share by Revenue, by Company (2021-2026)
Table 45. Australia RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million)
Table 46. Australia RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million)
Table 47. Alnylam Pharmaceuticals Company Details
Table 48. Alnylam Pharmaceuticals Business Overview
Table 49. Alnylam Pharmaceuticals RNAi for Therapeutic Product
Table 50. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 51. Alnylam Pharmaceuticals Recent Development
Table 52. Arrowhead Pharmaceuticals Company Details
Table 53. Arrowhead Pharmaceuticals Business Overview
Table 54. Arrowhead Pharmaceuticals RNAi for Therapeutic Product
Table 55. Arrowhead Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 56. Arrowhead Pharmaceuticals Recent Development
Table 57. Arrowhead Company Details
Table 58. Arrowhead Business Overview
Table 59. Arrowhead RNAi for Therapeutic Product
Table 60. Arrowhead Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 61. Arrowhead Recent Development
Table 62. Silence Therapeutics Company Details
Table 63. Silence Therapeutics Business Overview
Table 64. Silence Therapeutics RNAi for Therapeutic Product
Table 65. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 66. Silence Therapeutics Recent Development
Table 67. Benitec Biopharma Company Details
Table 68. Benitec Biopharma Business Overview
Table 69. Benitec Biopharma RNAi for Therapeutic Product
Table 70. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 71. Benitec Biopharma Recent Development
Table 72. Phio Pharmaceuticals Company Details
Table 73. Phio Pharmaceuticals Business Overview
Table 74. Phio Pharmaceuticals RNAi for Therapeutic Product
Table 75. Phio Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 76. Phio Pharmaceuticals Recent Development
Table 77. RXi Pharmaceuticals Company Details
Table 78. RXi Pharmaceuticals Business Overview
Table 79. RXi Pharmaceuticals RNAi for Therapeutic Product
Table 80. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 81. RXi Pharmaceuticals Recent Development
Table 82. Arrakis Therapeutics Company Details
Table 83. Arrakis Therapeutics Business Overview
Table 84. Arrakis Therapeutics RNAi for Therapeutic Product
Table 85. Arrakis Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 86. Arrakis Therapeutics Recent Development
Table 87. Benitec Biopharma Company Details
Table 88. Benitec Biopharma Business Overview
Table 89. Benitec Biopharma RNAi for Therapeutic Product
Table 90. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 91. Benitec Biopharma Recent Development
Table 92. miRagen Therapeutics Company Details
Table 93. miRagen Therapeutics Business Overview
Table 94. miRagen Therapeutics RNAi for Therapeutic Product
Table 95. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 96. miRagen Therapeutics Recent Development
Table 97. Sylentis Company Details
Table 98. Sylentis Business Overview
Table 99. Sylentis RNAi for Therapeutic Product
Table 100. Sylentis Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 101. Sylentis Recent Development
Table 102. Gradalis Company Details
Table 103. Gradalis Business Overview
Table 104. Gradalis RNAi for Therapeutic Product
Table 105. Gradalis Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 106. Gradalis Recent Development
Table 107. Sirnaomics Company Details
Table 108. Sirnaomics Business Overview
Table 109. Sirnaomics RNAi for Therapeutic Product
Table 110. Sirnaomics Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 111. Sirnaomics Recent Development
Table 112. Silenseed Company Details
Table 113. Silenseed Business Overview
Table 114. Silenseed RNAi for Therapeutic Product
Table 115. Silenseed Revenue in RNAi for Therapeutic Business (2021-2026) & (US$ Million)
Table 116. Silenseed Recent Development
Table 117. RNAi for Therapeutic Market Trends
Table 118. RNAi for Therapeutic Market Drivers
Table 119. RNAi for Therapeutic Market Challenges
Table 120. RNAi for Therapeutic Market Restraints
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
muLu

List of Figures

Figure 1. RNAi for Therapeutic Product Picture
Figure 2. Global RNAi for Therapeutic Market Share by Type: 2025 vs 2032
Figure 3. siRNA Features
Figure 4. miRNA Features
Figure 5. shRNA Features
Figure 6. Global RNAi for Therapeutic Market Share by Application: 2025 vs 2032
Figure 7. Cancer
Figure 8. Cardiovascular
Figure 9. HBV
Figure 10. Others
Figure 11. RNAi for Therapeutic Report Years Considered
Figure 12. Global RNAi for Therapeutic Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 13. Global RNAi for Therapeutic Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global RNAi for Therapeutic Market Share by Revenue, by Region: 2021 vs 2025
Figure 15. North America RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2021-2032)
Figure 16. Europe RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. China RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Japan RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Australia RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. Global RNAi for Therapeutic Market Share by Players in 2025
Figure 21. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2025)
Figure 22. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2025
Figure 23. North America RNAi for Therapeutic Market Share by Type (2021-2026)
Figure 24. North America RNAi for Therapeutic Market Share by Application (2021-2026)
Figure 25. Europe RNAi for Therapeutic Market Share by Type (2021-2026)
Figure 26. Europe RNAi for Therapeutic Market Share by Application (2021-2026)
Figure 27. China RNAi for Therapeutic Market Share by Type (2021-2026)
Figure 28. China RNAi for Therapeutic Market Share by Application (2021-2026)
Figure 29. Japan RNAi for Therapeutic Market Share by Type (2021-2026)
Figure 30. Japan RNAi for Therapeutic Market Share by Application (2021-2026)
Figure 31. Australia RNAi for Therapeutic Market Share by Type (2021-2026)
Figure 32. Australia RNAi for Therapeutic Market Share by Application (2021-2026)
Figure 33. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 34. Arrowhead Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 35. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 36. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 37. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 38. Phio Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 39. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 40. Arrakis Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 41. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 42. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 43. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 44. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 45. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 46. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2021-2026)
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
den_biaoTiZhungShi

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global RNAi for Therapeutic market?zhanKai
The top companies in the global RNAi for Therapeutic market are Alnylam Pharmaceuticals、Arrowhead Pharmaceuticals、Arrowhead.
What was the global market size of RNAi for Therapeutic in 2026?shouQi
What is the annual compound growth rate of the global RNAi for Therapeutic market size from 2026 to 2032?shouQi
Which region is expected to have the highest market share?shouQi
What was the global market size of RNAi for Therapeutic in 2032?shouQi
den_biaoTiZhungShi

Related Reports

Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Medical Care

Published Date: 2026-01-04

Pages: 100 Pages

Report ld: 5558885

CHOOSE LICENSE TYPE
tip

USD 4250.00

tip

USD 6375.00

tip

USD 8500.00

Add to Cart

Add to Cart

Buy Now

Buy Now

HAVE A QUESTION?
SIMON LEE

SIMON LEE

+1-62 6295 2442

English,Chinese

Offline

HITESH

HITESH

+91-86 6998 6909

English, Hindi

Offline

TANG XIN

TANG XIN

+81-90 3800 9273

Japanese,English

Offline

SUNG-BIN YOON

SUNG-BIN YOON

+82-2883 1278

Korean, English

Offline

YUJIE TIAN

YUJIE TIAN

+86-135-2215-3954

Chinese, English

Offline

DAMON

DAMON

+86-133 1872 9947

Chinese, English

Offline

General Email:
global@qyresearch.com

REPORT COVERAGE

den_ic8

DESCRIPTION

zhankai
den_ic7

OVERVIEW

den_ic7

MARKET SEGMENTATION

den_ic7

WHY THIS REPORT

den_ic7

QYRESEARCH'S STRENGTHS

den_ic8

TABLE OF CONTENTS

den_ic8

TABLE OF FIGURES

den_ic8

RLEATED REPORTS

INTEREST IN THIS REPORT?

yangBenGet A Free Sample

baoJia Request For Quotation

OR

NEED A CUSTOMIZED REPORT?

DingZhiCustomized Report

biaoTi

WORLD WIDE OFFICE

application for samples

Request Sample

Custom reports

Pre-Order Enquiry

Add to Cart

Add to Cart

Buy Now

Buy Now